Just saw 25,000 shares on the bid side. From what I have read, it is not a real bad news. The company still has a lot of potentials in the pipeline. Just like before, Big Boys will come scooping up cheap shares later.
It is known that Tiva works only in c-MET high patients and harms c-MET low patients.
Today data is for ITT (both c-MET high and c-MET low patients). This data is not very useful but
- ORR =45% is very high (almost like it was in 1st-line pts). This number will go higher for c-MET+ pts
- FPS was +1 month (hazard ratio = 0.85). It also will go higher for c-MET+
- OS is not reached in Tiva-arm. So it also will be good.
The management is poor
Data are promising
In 2 months, we will get the real picture
how much more bad news can these guys deliver? I don't know what to think of Pucci & crew at this point. I guess they were smart enough to raise money last year with good timing but some of these trials don't seem to make sense at all, at least in hindsight but then DS probably steering the ship at this point in that respect.. They seem to be claiming that the problem on cmet stratifying has been that there was no reliable way of doing it until Ventana solution last year. Today was bad but to honest when I saw the news this morning I thought sub $2 was a distinct possibility so $2.54 not bad in that respect.
Can you explain to me how this inept #$%$ Pucci still has a job?
How could they not do a pre-stratification for Met-group prior to this trial. The freakin' drug is a Met drug, and they're not even stratifying it?